Phase 4 N=10 The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
Healthy
Primary: Change in Brain Nicotinamide Adenine Dinucleotide Metabolites NAD+/NADH — -0.79 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=67 Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients
Schizophrenia, Undifferentiated Type
Primary: Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) — -0.25; -0.21; 3.8; 0.2 arbitrary units of activation
Phase 4 N=47 Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
Schizophrenia
Primary: Number of Participants With Changes in Fractional Anisotropy (FA) — 13; 9; 7 Participants
N/A N=11 Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers
Imaging of the Brain and Antipsychotics · Neuronal Network Changes
Primary: Repeatable Battery for the Assessment of Neuropsychological Status — -1.5; -0.5 RBANS T-Scale point difference
N/A N=76 PET and MRI Brain Imaging of Bipolar Disorder
Bipolar Disorder · Bipolar Depression · Unipolar Depression
Primary: Post-Lithium Treatment Hamilton Depression Rating Scale (HDRS) — -44.49 Percent Change in HDRS-24 Score
Phase 4 N=20 Brain Imaging of Quetiapine Response in Anxious Depression
Major Depression
Primary: 17-item Hamilton Depression Rating Scale (HDRS) — 20; 8 units on a scale
Phase 4 N=43 Neuroimaging of the Effects of Concerta in the Treatment of ADHD
Attention Deficit Disorder With Hyperactivity
Primary: Brain Oxygenation Level Dependent Signal in the Fusiform Gyrus and the Amygdala on Concerta vs. Placebo — 1.79; 0.58; 1.43; 0.77 Face-Shape BOLD signal difference
N/A N=50 Brain Imaging Techniques That Predict Antidepressant Responsiveness
Major Depressive Disorder
Primary: Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales — 20.07; 21.36; 1; 14.07 units on a scale
N/A N=165 Biomarkers in First Episode Schizophrenia
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder, Depressed Type
Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL
N/A N=189 Comparative Study of Conventional MR Images With Synthetically Reconstructed MR Images of the Brain
Clinical Indication for Brain MRI · Healthy Volunteers
Primary: Sensitivity of Pathological Findings (Full Analysis Set) — 0.66; 0.68 Proportion of participants
N/A N=82 Imaging Predictors of Treatment Response in Depression
Major Depressive Disorder
Primary: Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks — 12; 12 participants
Phase 4 N=40 Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging
Bipolar Disorder
Primary: Montgomery-Asberg Depression Rating Scale — -39.24 Percent change in MADRS from baseline
N/A N=12 The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study
Chronic Schizophrenia
Primary: Cognition on the RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) Scale — 7; 5.25; -1.5; -1.33 units on a scale
N/A N=43 Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Major Depressive Disorder
Primary: Fluorodopa Uptake Values in Brain Images of Aripiprazole Augmentation Responders — 1.297; 1.363; 1.333; 1.350 FDOPA ratio in the right medial caudate — p=0.029
N/A N=37 Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
Depression
Primary: Remission of Depressive Symptoms — 14; 14 participants
N/A N=93 Neuroplasticity in TBI and Schizophrenia
Schizophrenia · Traumatic Brain Injury
Primary: Mismatch Negativity (MMN) Amplitudes in Microvolts — -0.59; -1.19; -0.41; -0.65 microvolts
N/A N=33 Brain Imaging of rTMS Treatment for Depression
Major Depressive Disorder · Depression
Primary: Clinician Administered HAM-D — 27.0; 26.2; 22.0; 22.7 units on a scale
Phase 1 N=22 A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
Schizophrenia
Primary: Change From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA. — -0.0007; -0.0008; -0.0006; -0.0008 Kicer — p=0.0072
N/A N=10 Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
HIV · HIV-associated Neurocognitive Disorder · Neurotoxicity
Primary: Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS) — 19.38; 18.94; 27.83; 24.95 arbitrary units
N/A N=40 Imaging Biomarkers for TMS Treatment of Depression
Depression
Primary: Depressive Symptoms at 4 Weeks — 15.6; 15.6 units on a scale — p=0.16
N/A N=50 Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence
Cocaine Dependence
Primary: Change From Baseline in the Binding Potential of [11C]Raclopride — -13.7; -5.8 ratio — p=0.003
N/A N=19 PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
Borderline Personality Disorder
Primary: Change in Brain Metabolism From Baseline to Eight Weeks as Seen in PET Scan — 11.5 Standard uptake value — p=<0.05
Phase 3 N=218 Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
Healthy
Primary: Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid — 181; 0; 123; 58 Brain Scans Read
Phase 3 N=7 PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
Normal Pressure Hydrocephalus
Primary: Quantitative Estimates of Brain Uptake [18F]Flutemetamol and the Quantitative Immunohistochemical (IHC) Estimates of Amyloid Levels in Biopsy Samples Previously…
N/A N=28 Antidepressant Mechanisms of Transcranial Magnetic Stimulation
Depression
Primary: Depression Severity Measured by the Hamilton Depression Rating Scale (24-Item) — 18.2 units on a scale
Phase 1 N=12 PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
Schizophrenia
Primary: Change in Percentage Dopamine D2/D3 Receptor Occupancy — 36; 59; 2; 13 percentage occupancy
Phase 2 N=5 Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Diffuse Lewy Body Disease · Dementia With Lewy Bodies · Parkinson's Disease Dementia
Primary: Absolute 11C-PBR28 Binding (Total Distribution Volume Corrected for Free Fraction in Plasma) — 0.15 kBq·cm-3 / kBq·mL-1
Phase 4 N=50 Imaging the Migraine Brain Pre- and Post-Erenumab
Migraine
Primary: Resting State Functional Connectivity — 26.2; 23.3 global efficiency percentage — p=0.04
N/A N=190 Using Imaging to Assess Effects of THC on Brain Activity
Intoxication Alcohol · Intoxication THC · Intoxication Combined Alcohol THC
Primary: Change in Concentration of Oxygenated Hemoglobin Between Pre-drug and Post-drug Scans of Patients Completing the N-back Task. — 0.00000000042; -0.00000000126…
Phase 1 N=56 A Non-drug Methods Study in Participants With Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI) — 6.349…